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Abstract
Sandwich-cultured hepatocytes (SCH) are metabolically competent and have proper localization 
of basolateral and canalicular transporters with functional bile networks. Therefore, this cellular 
model is a unique tool that can be used to estimate biliary excretion of compounds. SCH have 
been used widely to assess hepatobiliary disposition of endogenous and exogenous compounds 
and metabolites. Mechanistic modeling based on SCH data enables estimation of metabolic and 
transporter-mediated clearances, which can be employed to construct physiologically-based 
pharmacokinetic models for prediction of drug disposition and drug-drug interactions in humans. 
In addition to pharmacokinetic studies, SCH also have been employed to study cytotoxicity and 
perturbation of biological processes by drugs and hepatically-generated metabolites. Human SCH 
can provide mechanistic insights underlying clinical drug-induced liver injury (DILI). In addition, 
data generated in SCH can be integrated into systems pharmacology models to predict potential 
DILI in humans. In this review, applications of SCH in studying hepatobiliary drug disposition and 
bile acid-mediated DILI are discussed. An example is presented to show how data generated in the 
SCH model was used to establish a quantitative relationship between intracellular bile acids and 
cytotoxicity, and how this information was incorporated into a systems pharmacology model for 
DILI prediction.
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INTRODUCTION
The liver is one of the major organs responsible for the metabolism and excretion of 
endogenous and exogenous molecules. Among many in vitro and in vivo model systems, 
primary hepatocytes remain the gold standard to assess hepatic drug metabolism and 
transport. Hepatocytes can be isolated from the species of interest, including humans, to 
address species differences in hepatic disposition of drugs. Primary hepatocytes express 
multiple metabolic enzymes and transporters, enabling assessment of overall hepatobiliary 
drug disposition. However, hepatocytes in suspension or under conventional culture 
conditions quickly lose cell polarity and viability, which limits their utility.1,2 Culturing 
hepatocytes between two layers of gelled collagen (sandwich configuration) improves 
morphology and viability of hepatocytes, and maintains function for longer periods of time 
in culture.3,4 In addition, sandwich-cultured hepatocytes (SCH) regain polarity, allowing 
proper localization of basolateral and canalicular transporters as well as formation of 
functional bile networks (Figure 1).5,6
When properly cultured, the expression and function of basolateral uptake transporters 
including sodium taurocholate co-transporting polypeptide (NTCP) and organic anion 
transporting polypeptides (OATPs) are maintained over time in human SCH,7–9 whereas 
down-regulation of Ntcp and Oatp has been reported for rat SCH.6,7 Upon isolation, 
hepatocytes lose biliary excretory function due to internalization of canalicular efflux 
transporters.10 However, canalicular transport proteins [e.g, bile salt export pump (BSEP/
Bsep), P-glycoprotein (P-gp), breast cancer resistance protein (BCRP/Bcrp), and multidrug 
resistance-associated protein (MRP/Mrp) 2] properly localize over time and regain excretory 
function in human and rat SCH.50 A schematic representation of hepatic transporters in SCH 
is shown in Figure 1. Phase I [i.e., cytochrome P450 (CYP)] and phase II [e.g., UDP-
glucuronosyltransferase (UGT), sulfotransferase (SULT)] metabolizing enzymes also are 
expressed in SCH, although some enzymes exhibit decreased expression and/or function 
over time in SCH compared to freshly isolated hepatocytes, depending on the culture 
conditions and medium composition.12–14 The influence of culture conditions and culture 
time on the expression and/or function of enzymes and transporters in the SCH system have 
been reviewed in detail elsewhere and are not the main focus of this manuscript.1,15,16
SCH provide a unique tool to estimate biliary excretion of compounds. Substances excreted 
into bile and accumulated in the canalicular network can be quantified by modulating tight 
junctions using buffer with and without calcium.17,18 Therefore, SCH have been used widely 
to assess hepatobiliary disposition of drugs and metabolites, and potential drug-drug 
interactions (DDIs). Transcriptional and post-translational regulatory machinery are well-
maintained in SCH, which makes it a suitable model for studying induction and feedback 
regulation of enzymes and transporters in response to compounds or other interventions.4,19 
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SCH that express functional metabolic enzymes also have been employed to study the 
pharmacology and toxicology of drugs and hepatically-generated metabolites. Because of 
the essential role of the liver in drug elimination, it is often a target organ of drug-induced 
toxicity. SCH have been used in the assessment of direct cytotoxicity and in mechanistic 
studies to determine perturbations of biological processes and to better understand 
underlying mechanisms of drug-induced liver injury (DILI).
In this manuscript, applications of SCH in studying hepatobiliary drug disposition and DILI 
are reviewed. First, use of the SCH system to characterize hepatic drug metabolism and 
transport is discussed. Predictions of in vivo drug disposition and clinical DDIs using SCH 
data combined with mechanistic and/or physiologically-based pharmacokinetic (PBPK) 
modeling also are reviewed. The use of SCH to study mechanisms underlying DILI is 
discussed with a focus on bile acid-drug interactions with hepatic transporters. An example 
of how SCH data can be used to develop a systems pharmacology model of DILI to predict 
clinical hepatotoxicity is introduced.
USE OF SANDWICH–CULTURED HEPATOCYTES IN STUDYING DRUG 
DISPOSITION
During drug discovery and development, assessment of metabolism and transport of new 
chemical entities is important to predict clinical exposure and potential DDIs. In this section, 
the use of SCH to study drug disposition is reviewed with a focus on metabolism and 
hepatobiliary transport of compounds and DDIs, and enzyme-transporter interplay. This 
section also highlights the estimation of enzyme- and transporter-mediated intrinsic 
clearance values using mechanistic pharmacokinetic modeling in addition to empirical 
methods. In vitro-in vivo extrapolation of intrinsic clearance and incorporation into PBPK 
modeling is discussed.
Metabolism
SCH have been used to study drug disposition, including hepatic uptake, metabolism and 
biliary excretion. Although human liver microsomes (HLMs), S9 subcellular fractions, and 
primary hepatocytes cultured in monolayers (without extracellular matrix overlay) are 
commonly used in metabolism studies of drugs and endogenous substrates, SCH are often 
used when extended incubation times (>24 hr) are needed, after which the viability and 
function of primary hepatocytes cultured in monolayers begin to deteriorate1. To 
demonstrate the applicability of SCH in predicting drug metabolism after extended 
exposure, the metabolic clearance values of low clearance drugs tolbutamide and warfarin, 
as well as a high clearance compound 7-ethoxycoumarin, were estimated using 
mathematical modeling after co-incubation with human SCH for 48 hr.20,21 The calculated 
intrinsic clearance was in accordance with literature reports. Another advantage of using 
SCH in drug metabolism studies is the presence of non-microsomal reductive enzymes, as 
demonstrated in a study of DB829. DB829, the active metabolite of an antitrypanosomal 
prodrug, was detected only in trace amounts in HLMs at the end of the 180-min incubation, 
but was detected readily in human SCH throughout the 24-hr incubation.22
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Metabolism-Mediated DDIs—Both inhibition- and induction-mediated DDIs have been 
studied using SCH. The CYP substrates used in these studies generally penetrate the 
hepatocytes via passive diffusion to eliminate the confounding effect of transporters. 
Although CYP inhibition has been studied primarily using HLMs, a few studies using SCH 
have been reported. The inhibitory effect of tritolide on CYP3A was evaluated by Shen et 
al.23 Both the expression and activity (measured by midazolam hydroxylation) of CYP3A in 
rat SCH were reduced after exposure to tritolide for up to 24 hr. Bi et al. 24 reported that the 
intracellular accumulation of buprenorphine and midazolam in human SCH was increased 
by rifamycin SV due to inhibition of CYP3A4 and UGT1A1, which mediate the metabolism 
of these two victim substrates. SCH allow for longer exposure time, making them suitable 
for CYP induction studies. For example, the activity of CYP3A was assessed in human SCH 
after incubation with pregnancy-related hormones for 72 hr.25
Hepatobiliary Transport
Mechanisms of Hepatobiliary Disposition—Under appropriate culture conditions, 
SCH express key transport proteins that are properly localized, and therefore, they are 
uniquely advantageous to study the mechanisms of hepatobiliary transport of a compound as 
well as the effects of a compound on hepatobiliary transporters. SCH isolated from naturally 
occurring genetically deficient rodents [e.g., Mrp2-deficient Wistar rats (TR− rats), Eisai-
hyperbilirubinemic Sprague-Dawley rats (EHBR rats)] or genetically modified animals with 
loss-of-function of a specific transporter can be used to elucidate the role of that transporter 
in the disposition of a compound.26,27 Knockdown of Bcrp using RNA interference in SCH 
isolated from wild-type rats elucidated the role of Bcrp in drug hepatobiliary 
disposition.28,29 With human SCH, the role of individual transporters can be determined by 
using “specific” transporter inhibitors or by modifying the experimental conditions. For 
example, the role of NTCP could be assessed by measuring uptake in the absence and 
presence of sodium. However, highly specific transport inhibitors and substrates are lacking, 
and genetically modified animals are only limited to a few transporters. Therefore, a multi-
experimental approach integrating SCH data, transfected systems and membrane vesicles 
can be used to characterize the involvement of multiple transporters.26,27 Understanding the 
transport mechanism(s) could facilitate identification of potential DDIs involving uptake and 
efflux transporters. Previous reviews have shown the utility of SCH for these 
applications,1,15 and recent reports are discussed below. A focused discussion about drug 
effects on bile acid disposition is in the following section “Mechanistic Investigations of Bile 
Acid-Mediated DILI”.
Yanni et al. identified the hepatic transporters involved in micafungin disposition by co-
incubation of micafungin with an NTCP inhibitor [taurocholic acid (TCA)], an OATP 
inhibitor (rifampin), BSEP inhibitors (TCA and nefazodone), a mixed P-gp/BCRP inhibitor 
(GF120918), as well as a P-gp and MRP2 inhibitor (cyclosporine A).31 Mohamed et al. 
reported that the disposition of tacrine, which was approved for treatment of Alzheimer’s 
disease, was mediated by Octs, Mrp2 and P-gp by using rat SCH and chemical inhibitors.32 
A similar approach to elucidate the responsible hepatobiliary transporters for 17α-
hydroxyprogesterone caproate and its effect on bile acid transporters has been reported.33 
One caveat with this type of approach is that these “specific” inhibitors may have other 
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effects on metabolism and/or transport. To overcome this issue, transporter assays using 
transfected cells can be used to confirm findings from the SCH studies. For example, 
disposition of a natural product timosaponin b2 (TB2) was characterized using rat SCH and 
involvement of specific transporters was confirmed using human OATP1B1- and OATP1B3-
expressing HEK-293 cells and membrane vesicles isolated from cells expressing human 
MRP2 and BCRP.34
In addition to drugs, the disposition of endogenous compounds has been studied using SCH. 
For example, amyloid-β (Aβ) hepatic disposition was studied in human SCH since Aβ 
accumulation contributes to Alzheimer’s disease.35 Aβ was found to be taken up primarily 
by low-density lipoprotein receptor-related protein-1 (LRP1), and effluxed by P-gp. This 
finding indicates that enhancement of Aβ hepatic clearance via LRP1 and P-gp induction 
could be a novel therapeutic approach for the prevention and treatment of Alzheimer’s 
disease. Toxic compounds such as arsenic also have been studied in human SCH. The results 
suggest that arsenic basolateral efflux prevails over biliary excretion, and is mediated at least 
in part by MRPs, most likely MRP4.36
Estimation of Transport Clearance—In the estimation of uptake clearance, 
hepatocytes in suspension generally are preferred due to the ease of use 37,38 and concerns 
regarding down-regulation of uptake transporters in rat SCH.7 However, uptake transporter 
function in human SCH remains similar to freshly isolated hepatocytes under appropriate 
culture conditions.6,7 Recent evidence suggests that cryopreserved hepatocytes cultured in 
sandwich configuration are a more feasible research tool to evaluate in vitro transport 
parameters without the negative impact derived from membrane leakage during 
cryopreservation.9 To distinguish active uptake from passive diffusion, hepatocytes can be 
co-incubated with an OATP inhibitor if the active uptake is mediated mainly by OATP. For 
example, rifampicin SV (100 μM) was reported to block OATP function in OATP-
transfected cell lines and human SCH without affecting the passive diffusion.24,39 
Alternatively, active uptake in SCH can be determined by the difference in uptake in the 
absence and presence of sodium if the active uptake is governed primarily by NTCP. Active 
uptake also may be differentiated from passive diffusion by comparing the difference in 
uptake determined at 37°C and 4°C. However, reduced uptake at 4°C might be an artificial 
effect of a more rigid cell membrane, and thus, active uptake using this approach may be 
over-estimated.40
In SCH, the biliary efflux clearance and biliary excretion index (BEI) can be calculated 
using B-CLEAR® technology and Equations 1–3.41 A detailed description of B-CLEAR® 
technology, including an overview of the advantages and limitations has been published by 
Swift et al.1 Essentially, the accumulation of compound in cells + bile canaliculi and the 
accumulation of compound in cells can be differentiated by modulating the tight junctions 
using Ca2+-containing and Ca2+-free Hank’s balanced salt solution (HBSS). The utility of 
SCH data for extrapolation from in vitro biliary clearance to in vivo biliary clearance was 
reviewed previously by De Bruyn et al.15
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Eq. 1
Eq. 2
Eq. 3
CLb, app, in vitro and CLb, int, in vitro represent in vitro apparent biliary clearance and in vitro 
intrinsic biliary clearance, respectively. BEI represents biliary excretion index, which is the 
fraction of compound accumulated in the bile compartment relative to the total accumulation 
in cells plus bile.
Use of the SCH assay to categorize compounds as low, intermediate or high biliary clearance 
was first reported by Liu et al41, and has been confirmed by numerous investigators and 
reviewed by De Bruyn et al. 15 and Swift et al.1 Pan et al.42 evaluated the biliary clearance of 
110 compounds from Novartis exhibiting different permeability properties using the rat SCH 
model. The predicted biliary clearance from rat SCH correlated well with in vivo rat data, 
except for underestimation of biliary clearance for compounds with extremely low passive 
permeability and metabolism. The rank order of biliary clearance from human SCH data 
corresponded with clinical data for compounds with low to high biliary clearance,43 despite 
slight underestimation of the absolute values (by 50–80%). The underestimation might be 
due to the decreased activity of uptake transporters depending on the culture conditions, and 
use of compound concentrations in the medium (Eq.1) instead of the intracellular 
concentrations (Eq.2) to predict biliary clearance. More accurate estimates of biliary 
clearance parameters for in vitro-in vivo scaling are discussed in greater detail in the 
“Mechanistic and PBPK Modeling” section.
To improve the accuracy of biliary clearance predictions using both rat and human SCH, the 
following approaches have been reported. The correlation between in vitro and in vivo 
biliary clearance is improved by using unbound plasma concentrations in the estimation of 
in vivo biliary clearance.44 Moreover, the difference between in vivo intrinsic biliary 
clearance and predicted intrinsic biliary clearance from the SCH data using Eq. 2 is smaller 
than the difference between in vivo apparent biliary clearance and predicted apparent biliary 
clearance from SCH data based on Eq. 1.45 Therefore, in vitro intrinsic biliary clearance 
(calculated based on intracellular concentrations instead of medium concentrations) is more 
reflective of in vivo biliary clearance.45 In addition, quantitative proteomic approaches have 
been applied to improve biliary clearance predictions, as discussed in detail in the 
“Mechanistic and PBPK Modeling” section.
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Basolateral efflux clearance can be estimated by preloading SCH with a substrate, and 
measuring the medium concentration at the end of the efflux phase. Ferslew et al. estimated 
basolateral efflux clearance of enalaprilat (generated in hepatocytes after incubation of rat 
SCH with enalapril) based on the cumulative amount of enalaprilat effluxed into the medium 
and intracellular enalaprilat concentrations over the efflux period.46 The functional 
importance of MRP4 in the basolateral efflux of enalaprilat was demonstrated by using 
MK-571, an inhibitor of multiple MRPs, in rat SCH, and confirmed in membrane vesicles 
prepared from HEK-293 cells overexpressing human MRP4. Of note, direct estimation of 
basolateral efflux using this approach was possible because biliary excretion of enalaprilat is 
negligible. For compounds that undergo extensive biliary excretion, mechanistic modeling is 
necessary to deconvolute basolateral efflux, biliary excretion, and flux from the bile 
compartment to the medium, as discussed in the “Mechanistic and PBPK Modeling” section.
Transporter-Mediated DDIs—Transporter-based drug-drug and drug-bile acid 
interactions may have significant toxicological implications, such as statin-induced 
myopathy and rhabdomyolysis due to inhibition of OATPs,47 and troglitazone (TGZ)- and 
bosentan-induced hepatotoxicity due to inhibition of BSEP.48,49 Membrane vesicles 
prepared from transfected cells overexpressing relevant transport proteins are useful to 
characterize substrate specificity and inhibitory potency of a given transport protein in 
isolation. However, a more physiologically representative, organ-specific, whole-cell system 
is needed to elucidate the relative contribution of individual transporters to overall clearance, 
and to estimate the net effect of inhibition/induction at multiple sites. Both acute (direct and 
indirect) and long-term effects on transporters have been studied in SCH.
A DDI between ritonavir (perpetrator) and 99mTc–mebrofenin (victim substrate) due to 
direct inhibition was demonstrated by Pfeifer et al. using human SCH coupled with 
modeling and simulation of clinical data.6,50 Ritonavir decreased 99mTc–mebrofenin uptake 
without changing the BEI of 99mTc–mebrofenin, despite the fact that ritonavir had been 
reported to inhibit MRP2, which mediates the biliary excretion of 99mTc–mebrofenin. These 
in vitro findings were consistent with the clinical observation that single or multiple doses of 
ritonavir increased 99mTc–mebrofenin systemic exposure without significantly changing 
biliary recovery of 99mTc–mebrofenin. SCH data revealed that intracellular ritonavir 
concentrations after clinical doses were not high enough to inhibit MRP2 based on data 
generated for 99mTc–mebrofenin transport by MRP2.
Unlike direct inhibition, indirect inhibition of transporters is under-appreciated and the 
relevant studies using SCH are still limited. Powell et al 51 reported post-translational 
regulation of OATP1B3 by the protein kinase C (PKC) activator, phorbol-12-myristate-13-
acetate (PMA). This mechanism was revealed by the fact that pre-treatment of SCH with 
PMA inhibited OATP1B3 function while co-incubation with PMA did not. Kruglov et al. 
reported that the type II inositol 1,4,5-trisphosphate receptor modulates Bsep activity in rat 
SCH through post-translational regulation.52 The important role of N-glycosylation of ATP-
binding cassette transporters on transport activity was established using rat SCH.53,54
The induction of transporters after long-term incubation (>24 hr) also was studied in SCH. 
Up-regulation of transporter mRNA expression in response to prototypical activators of the 
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pregnane X receptor, aryl hydrocarbon receptor and constitutive androstane receptor were 
reported in mouse SCH.55 In addition to changes in mRNA expression of P-gp, an increase 
in the BEI of digoxin, a P-gp substrate, was observed in human SCH following treatment 
with rifampicin for 3 days.56
Enzyme-Transporter Interplay
The complexity of DDI predictions may be increased further by the interplay between 
enzymes and transporters. Many compounds interact with enzymes and transporters 
simultaneously. For example, cyclosporine inhibits CYP3A4, and multiple transporters 
including P-gp and OATP1B1. Gemfibrozil and gemfibrozil glucuronide inhibit CYP2C8 
and OATP1B1.47 Moreover, the parent compound and derived metabolites may have similar 
or opposite effects on transporters and enzymes. For drugs that are metabolized extensively, 
the presence of metabolic capacity in SCH enables the simultaneous evaluation of parent and 
metabolite effects without prior knowledge regarding the metabolites. This capability is very 
beneficial, especially in the early stages of drug discovery when metabolite identification has 
not been conducted and purified metabolites are not available. A few examples are discussed 
below.
For drugs that are rapidly metabolized and the metabolites are not transporter inhibitors, the 
intracellular concentration of the parent compound might not be high enough to inhibit 
efflux transporters. For example, cilexetil (CIL) exhibited potent BSEP inhibition based on 
membrane vesicle assays. However, BSEP inhibition by CIL was not observed in human 
SCH after 120-min exposure, which might be due to the metabolic elimination of CIL in 
SCH.57 In this case, the membrane vesicle data led to a false positive prediction of BSEP 
inhibition. Sometimes metabolites are more potent inhibitors of transporters, such as TGZ 
sulfate vs. TGZ. In this case, data from a metabolism-deficient system could lead to false-
negative results.49 The interplay between formation and excretion of TGZ metabolites was 
studied in rat SCH lacking Bcrp and Mrp2 by Yang et al. using RNA interference techniques 
to knock down Bcrp in SCH prepared from TR− rats.58 In some cases, only the metabolites 
are transporter inhibitors. For example, although estradiol and bilirubin do not inhibit 
MRP2, pre-exposure of rat SCH to estradiol and bilirubin decreased the biliary excretion of 
5-(and 6)-carboxy-2′,7′-dichlorofluorescein, a MRP2 substrate, which could be attributed to 
the inhibition by the generated metabolites of estradiol and bilirubin. 59
Mechanistic and PBPK Modeling
Physiologically based pharmacokinetic (PBPK) modeling is a useful tool to predict the 
pharmacokinetics of novel compounds in the systemic circulation and target organs. 
Successful PBPK models depend on reliable estimates of compound-specific information 
(e.g., clearance, tissue partition coefficients, and the rate and extent of absorption). SCH 
have been used to estimate clearance values that are incorporated into PBPK models. The 
methods to estimate in vitro clearance using SCH and extrapolate from in vitro to in vivo 
clearance values are discussed below.
In vitro intrinsic uptake and efflux clearance values have been estimated using empirical 
methods, as described in the previous sections. The apparent clearance value determined 
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from SCH data may be comprised of more than one clearance pathway. Despite this 
limitation, clearance values estimated by empirical/static approaches can represent useful 
prior information to guide the experimental design for mechanistic modeling and simulation, 
and generally requires a relatively small number of data points.
Mechanistic pharmacokinetic models have been developed to deconvolute apparent uptake 
and efflux clearance values and obtain more accurate estimates. Linear kinetics are assumed 
and the clearance terms (rather than Vmax and Km) are used because a single, low 
concentration of substrate typically is studied. To estimate the kinetic parameters, multiple 
time points during both the uptake and efflux phase are required. Depending on the 
permeability of the substrate, passive diffusion clearance could be estimated solely from 
37°C data. The kinetic parameters estimated could be used to perform sensitivity analyses 
and Monte Carlo simulations, which can help identify key model input parameters. 
Depending on the model structure and complexity, the published mechanistic 
pharmacokinetic models are classified into three categories. The model structures and 
exemplar experimental protocols are shown in Figure 2; the model output parameters, 
assumptions and applications of each model are summarized in Table 1.
Model I—This model is the simplest for the SCH system (Figure 2A). Three compartments 
represent the medium, cell, and bile, with passive diffusion, active uptake, biliary efflux, and 
metabolism processes included. Key kinetic parameters include intrinsic passive diffusion 
clearance (CLint, pass); intrinsic uptake clearance (CLint, uptake), and intrinsic biliary 
clearance (CLint, bile). Basolateral efflux is assumed to be negligible. When significant 
metabolism is observed, intrinsic metabolic clearance (CLint, met) is set to the unbound 
intrinsic clearance value determined in HLMs. To generate the experimental data, SCH are 
first pre-incubated with standard HBSS, Ca2+-free HBSS, or standard HBSS containing 
rifamycin SV, followed by incubation with the substrate. Substrate uptake is terminated at 
different time points, and the intracellular and medium concentrations of the substrate are 
measured. This model has been applied to estimate the in vitro intrinsic clearance for OATP 
substrates by several research groups.60–62
Model II—Unlike Model I where CLint, met is fixed to a pre-determined value, CLint, met is 
fitted to metabolite(s) concentration- time data in Model II. In addition, intrinsic basolateral 
efflux clearance of metabolite (CLint, BL, metabolite) is included rather than assuming passive 
diffusion. Kflux, metabolite, which accounts for the “flux” of metabolite from the canalicular 
compartment into the buffer, also is incorporated. 68–70 In this model, it is assumed that only 
metabolites undergo efflux into bile or medium. (Figure 2B). The experimental protocol is 
similar to that of Model I except that the pre-incubation phase only consists of two 
conditions (HBSS and Ca2+-free HBSS) and both parent and metabolite(s) concentrations 
are measured. Lee et al. fitted this model to concentration-time data for TGZ and metabolites 
[TGZ sulfate, TGZ glucuronide, and TGZ quinone] in rat and human SCH.63 This model 
has been used to characterize the contribution of individual clearance pathways to the 
disposition of mycophenolic acid (MPA) and MPA glucuronide (MPAG), 64 and the 
inhibitory potency of cyclosporine on each pathway in human SCH. 67 The modeling results 
suggest that cyclosporine A inhibits both basolateral uptake and biliary efflux clearance of 
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MPAG without changing the conversion of MPA to MPAG. This mechanism explains the 
cyclosporine A-mediated decrease in enterohepatic circulation of MPAG and lower systemic 
exposure of MPA and MPAG in humans.
Model III—Model III is more suitable for compounds with minimal passive diffusion that 
are not extensively metabolized (Figure 2C), such as rosuvastatin (RSV) and TCA. To obtain 
an accurate estimate of basolateral efflux, a novel uptake and efflux protocol is used, which 
includes an uptake phase followed by an efflux phase where serial samples are obtained. 
Uptake, biliary, and basolateral efflux clearance values for RSV, 3H-TCA, and d8-TCA were 
estimated from rat and human SCH data. 65–67 The impact of impaired clearance of RSV 
and 3H-TCA were simulated, and predicted perpetrator effects on d8-TCA disposition were 
compared with experimental observations.
In this experimental design, a few practical factors need to be considered for determining the 
maximum incubation time. Most of the time, the uptake phase is extended beyond the linear 
range to attain steady-state intracellular conditions, which reduces the error in certain 
parameter estimates observed with shorter incubation times. 71 However, exposure to Ca2+-
free HBSS for more than 30 min increases cytotoxicity.1 Therefore, after pre-incubation 
with Ca2+-containing or Ca2+-free HBSS for 10 min, SCH are incubated with Ca2+-
containing HBSS during the uptake phase. The uptake phase should be limited to 20 min in 
Ca2+-containing HBSS to avoid resealing of tight junctions in SCH pre-incubated with 
Ca2+-free HBSS.65
Scaling Methods—In vivo intrinsic clearance is a key parameter for PBPK models that 
can be extrapolated from in vitro clearance using the following scaling methods. The 
simplest and most straightforward approach of scaling up is based on hepatocellularity and 
liver weight as described previously72 and reviewed by Poulin.73 Scaling with physiological 
parameters works well for metabolic clearance. However, this approach leads to an 
underprediction of CLint, uptake and an overprediction of CLint, bile.
60
 Underprediction of 
uptake may be due to disregarding CLint, BL in the model, or to down-regulation of uptake 
transporters in vitro compared to in vivo14. Overprediction of CLint, bile may be due the 
absence of enterohepatic recirculation, and/or ignoring Kflux in the mechanistic model.
60 
Clearly, over-simplification of the model structure can lead to over- or under-prediction of 
parameters. To address this issue, Jones et al. determined compound-specific empirical 
scaling factors (SFs) by comparing in vivo clearance estimated from intravenous 
pharmacokinetic data to in vitro clearance data;60 geometric mean SFs for intrinsic unbound 
uptake clearance (CLint, u, uptake), intrinsic unbound biliary clearance (CLint, u, bile) and 
intrinsic unbound passive diffusion clearance (CLint, u, pass) of seven OATP substrates were 
reported as 58, 0.061, and 1.60 These SFs have been used in the in vitro-in vivo extrapolation 
of other OATP substrates such as telmisartan.60,61 A similar approach has been applied to 
estimate SFs for CLint, uptake of pravastatin, repaglinide, and glyburide.
74
–
76
 Li et al. 
developed a single set of empirical SFs by simultaneously modeling data for the same seven 
OATP substrates; they reported SFs of 55 for CLint, u, uptake, 0.019 for CLint, u, bile, and 0.092 
for CLint, u, pass.
77
 The difference in the estimated SF for CLint, u, pass between the two 
studies (1 vs. 0.092) could be due to different approaches for model fitting [the SF for 
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intrinsic unbound metabolic clearance (CLint, u, met) was not estimated by Jones et al.60 
because CLint, u, met was not identifiable, but this SF was fitted in the work of Li et al.
77]
The approach described above relies on intravenous pharmacokinetic data to estimate 
empirical SFs. If intravenous data are not available, the in vitro-in vivo extrapolation could 
be facilitated by information regarding transporter abundance. Absolute quantification of 
transporter expression by mass spectrometry was first reported by Terasaki and colleagues, 
based on the assumption that all expressed protein is localized on the membrane and, 
therefore, functional.78–82 This technique has been advanced by the work of Lai and 
coworkers,10, 13,24,83 Unadkat and colleagues 78,79 and more recently by Artursson and 
coworkers 84 and Galetin and colleagues.85
Intrinsic clearance values estimated using the approaches detailed above can be used directly 
in PBPK models 86 or they can be combined with liver blood flow and protein binding data 
to estimate hepatic clearance based on the well-stirred or parallel-tube models of hepatic 
disposition.87 Pharmacokinetic profiles have been predicted successfully for numerous 
compounds including statins, sartans, mebrofenin, pafuramidine, glyburide, and repaglinide 
using PBPK models that incorporated clearance values estimated from 
SCH.24,50,60–62,74–76,88–91
USE OF SANDWICH–CULTURED HEPATOCYTES TO STUDY DRUG–
INDUCED LIVER INJURY
Drug-induced liver injury (DILI) is the most common cause of acute fulminant hepatic 
failure,94 and is the primary reason for withdrawal of approved drugs from the market.95 
DILI is one of the major challenges during drug development because standard preclinical 
testing has not been able to precisely predict clinical DILI and mechanisms underlying 
interspecies differences have not been fully elucidated. DILI manifests as a broad spectrum 
of liver injuries, and multiple mechanisms may cause DILI including oxidative stress, 
mitochondrial toxicity, and bile acid transporter inhibition.96,97 Therefore, many different 
approaches and experimental systems have been used to predict the hepatotoxic potential of 
compounds. SCH are a useful tool to assess cytotoxicity and perturbation of biological 
processes by drugs and hepatically-generated metabolites, providing mechanistic insights 
into hepatotoxicity.98–100 This system also allows direct sampling of hepatocytes for 
measurement of intracellular drug exposure or cytotoxicity endpoints such as ATP.
In this section, use of SCH to study DILI is reviewed with a focus on bile acid-mediated 
hepatotoxicity. Mechanistic investigations of altered bile acid disposition by drugs using 
SCH and mechanistic modeling are reviewed first. Next, use of systems pharmacology 
modeling to predict clinical DILI is discussed. An example of how the SCH model was used 
to establish a quantitative relationship between intracellular bile acids and toxicity in a 
systems pharmacology model is presented using novel unpublished data generated in our 
laboratory.
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Mechanistic Investigations of Bile Acid-Mediated DILI
One proposed mechanism of DILI is inhibition of bile acid efflux in hepatocytes by drugs, 
which may result in intracellular accumulation of potentially toxic bile acids.101,102 
Evidence continues to accumulate that inhibition of bile acid transporters such as BSEP and 
MRPs by drugs is a risk factor for DILI.103–106 Bile acids play important roles in the body 
as key signaling molecules as well as lipid solubilizers, but bile acids can be cytotoxic when 
present at supraphysiologic concentrations in hepatocytes.107 Bile acid toxicity is highly 
correlated with hydrophobicity; lithocholic acid (LCA), chenodeoxycholic acid (CDCA), 
and deoxycholic acid (DCA) are more cytotoxic than less hydrophobic bile acids, cholic acid 
(CA) and ursodeoxycholic acid (UDCA).101,108,109 Mechanisms of bile acid-induced 
hepatotoxicity include disruption of cell membranes due to their detergent-like properties, 
disruption of mitochondrial ATP synthesis, necrosis, and apoptosis.101
Hepatic enzymes and transport proteins play important roles in metabolism and excretion of 
bile acids.110–113 SCH express bile acid metabolizing enzymes and transporters, and are 
capable of synthesizing, metabolizing, and transporting bile acids.114 SCH also can be 
isolated from different species, enabling investigation of species differences in hepatobiliary 
bile acid disposition and drug-bile acid interactions, as reviewed in the following section.
Characterization of Hepatobiliary Bile Acid Disposition in SCH—Vectorial 
transport of bile acids is mediated primarily by the hepatic uptake transporter NTCP and the 
canalicular efflux transporter BSEP.111,112 In addition to BSEP-mediated biliary excretion, 
bile acids also can be transported into sinusoidal blood by MRP3, MRP4, and organic solute 
transporter (OST)α/β.115–118 Due to extensive biliary excretion, the contribution of 
basolateral efflux to hepatocellular bile acid excretion was presumed to be minimal. 
However, mechanistic modeling based on TCA disposition data in rat SCH demonstrated 
that CLint, bile and CLint, BL of TCA are similar (0.34 and 0.26 mL/min/gram liver, 
respectively).119 These data suggest that biliary excretion and basolateral efflux contribute 
almost equally to hepatocellular excretion of TCA in rat SCH. Bile acids transported into 
sinusoidal blood can subsequently be taken up by downstream hepatocytes. After 
undergoing blood-liver cycling as they move from the periportal to the centrilobular zone, 
the majority of bile acids eventually are excreted into bile, similar to the “hepatocyte 
hopping” of bilirubin glucuronides.120 In contrast, biliary excretion of TCA predominated in 
human SCH (CLint, bile=0.14 mL/min/gram liver and CLint, BL=0.042 mL/min/gram liver), 
indicating that species differences exist in the hepatocellular excretion of bile acids in rats 
vs. humans.119
SCH also can be used to investigate bile acid disposition in hepatocytes from special 
populations such as the fetus. Sharma et al. showed that the BEI of TCA, a BSEP substrate, 
in fetal hepatocytes was approximately one-half of that in adult hepatocytes (36 and 72%, 
respectively).121 RT-PCR analysis demonstrated that mRNA expression of ABCB11 (a gene 
encoding BSEP) in fetal hepatocytes was 40% of that in adult hepatocytes, consistent with 
the functional study results.121
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Evaluation of Drug Effects on Hepatobiliary Bile Acid Disposition using SCH
—Drug effects on bile acid transport can be evaluated using multiple in vitro systems. 
Isolated membrane vesicles overexpressing a specific transporter (e.g., BSEP, MRP3, 
MRP4) have been used widely to assess drug-bile acid interactions that involve efflux 
transporters.103,104,106,122 To assess drug effects on hepatic uptake of bile acids, cell lines 
overexpressing uptake transporters (e.g., NTCP) are employed. These transporter-
overexpressing systems provide a useful tool to study drug-bile acid interactions for a single 
transporter, and to estimate kinetic parameters of bile acid transport and drug-mediated 
inhibition [e.g., Michaelis-Menten constant (Km), inhibition constant (Ki), half-maximal 
inhibitory concentration (IC50)]. However, it is difficult to assess the “net effect” of drugs on 
hepatobiliary bile acid disposition using these systems because multiple uptake and efflux 
transporters are involved in bile acid disposition. SCH, which express functional bile acid 
transporters on the basolateral and canalicular membranes, are suitable for this purpose. 
SCH also express functional metabolic enzymes and allow evaluation of drug metabolite 
effects on bile acid transporters, which is advantageous when the metabolic pathways have 
not been characterized and/or the specific effects of metabolites are unknown.
SCH have been used widely to determine altered bile acid disposition by drugs that belong 
to different therapeutic classes. Endothelin receptor antagonists (ERAs) are used to manage 
pulmonary arterial hypertension. Despite their clinical benefits, some ERAs have been 
associated with hepatotoxicity, although the incidence rate and severity appears to be 
compound-specific. Sitaxsentan was withdrawn from the market recently due to cases of 
fatal hepatotoxicity, and bosentan requires monthly monitoring due to serum 
aminotransferase elevations in a subset of patients.123–125 Inhibition of bile acid transporters 
has been proposed as an underlying mechanism of sitaxsentan- and bosentan-mediated 
DILI.103,126,127 On the other hand, recently approved ERAs, ambrisentan and macitentan, 
are associated with a lower risk of liver injury.128–130 Studies using human SCH 
demonstrated that individual ERAs have differential effects on the hepatobiliary disposition 
of bile acids. In human SCH, bosentan and macitentan significantly decreased the BEI and 
apparent biliary clearance of TCA, whereas ambrisentan showed minimal inhibitory effects 
on TCA biliary excretion.30 Bosentan and sitaxsentan also significantly inhibited sodium-
dependent TCA uptake in human SCH.30 As a result of inhibitory effects on multiple bile 
acid transporters, bosentan and macitentan significantly decreased total (cell + bile) and 
cellular accumulation of TCA in human SCH in a concentration-dependent manner.30 
Interestingly, individual ERAs accumulated in human SCH to a different extent; the 
hepatocyte concentration of macitentan was about 100-fold greater than the medium 
concentration followed by sitaxsentan (40-fold), bosentan (20-fold), and ambrisentan (2-
fold).26 The low incidence of macitentan hepatotoxicity in the clinic may be due to the low 
dose and relatively lower exposure compared to the other ERAs. Hepatocyte concentrations 
of these inhibitors at clinically relevant doses need to be investigated to confirm this 
hypothesis.
Antiretroviral protease inhibitors (PIs) are commonly used to treat human immunodeficiency 
virus, but in a subset of patients, their clinical use is limited due to DILI.132–134 Ritonavir is 
often administered with other PIs to improve oral bioavailability of the coadministered PIs, 
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but ritonavir-containing regimens are associated with an 8.6-fold increase in the risk of 
hepatotoxicity.133 Several PIs including ritonavir and lopinavir are known to inhibit 
BSEP,103,135 suggesting that hepatotoxicity is mediated, in part, by bile acid transport 
inhibition. Studies in rat SCH demonstrated that ritonavir and lopinavir significantly reduced 
TCA biliary excretion (BEI and CLb, app, in vitro) and subsequently, increased intracellular 
accumulation of TCA.136 Co-incubation of both lopinavir and ritonavir further decreased 
biliary excretion, resulting in increased cellular TCA accumulation.136 Interestingly, 24-hr 
exposure to lopinavir and ritonavir decreased hepatic accumulation of endogenous bile acids 
in rat SCH, potentially due to protective feedback regulation that reduced hepatic bile acid 
synthesis.136
TAK-875 is a selective G-protein-coupled receptor 40 agonist that was developed to treat 
type 2 diabetes, but the clinical development of TAK-875 was discontinued due to 
hepatotoxicity concerns. Studies using rat SCH demonstrated that TAK-875 decreased 
CLb, app, in vitro and BEI of TCA, suggesting that inhibition of bile acid transport may be 
responsible, in part, for the hepatotoxicity of this compound.137
Guo et al. reported that alpha-naphthylisothiocyanate (ANIT), a model cholestatic 
compound, induced total bile acid accumulation in rat SCH after a 48-hr incubation, which 
was consistent with elevated total serum bile acids after in vivo exposure in rats. This effect 
of ANIT was probably due to inhibition of Ntcp, Oatp1a4 and/or Oatp1a1, Mrp2, and Mrp3, 
as demonstrated by using prototypical transporter substrates, but not because of increased 
bile acid synthesis, as evidenced by decreased mRNA expression of enzymes governing bile 
acid synthesis (i.e., Cyp7a1, Cyp27a1, and Cyp8b1).138
Investigation of a panel of endpoints in SCH (e.g., BEI, CLb, app, in vitro, total and cellular 
accumulation of bile acids) provides mechanistic information about potential sites (uptake or 
excretion) of bile acid transporter modulation by compounds. For example, if a compound 
inhibits both uptake (indicated by a decrease in total accumulation and CLb, app, in vitro) and 
biliary excretion (indicated by a decrease in BEI and CLb, app, in vitro) of bile acids, an 
increase in cellular accumulation of bile acids suggests that the compound predominantly 
influences biliary excretion. On the other hand, a decrease in the cellular accumulation of 
bile acids indicates that bile acid uptake is primarily affected. Ansede et al. investigated the 
effects of TGZ, glyburide, cyclosporine A, and erythromycin estolate on the disposition of 
the model bile acid TCA in rat SCH. These compounds had been shown to inhibit hepatic 
bile acid transporters in isolated vesicular systems or suspended hepatocytes.103,104,139,140 
Based on SCH data using endpoint analysis, as described above, cyclosporine A and 
glyburide inhibited biliary excretion to a greater extent than hepatic uptake of TCA. On the 
other hand, erythromycin estolate and TGZ primarily affected TCA uptake.140,141 These 
examples demonstrate that unlike other in vitro transporter models, SCH can be used to 
simultaneously determine the effects of a drug on the basolateral uptake and biliary 
excretion of bile acids, and therefore, the overall effect of drugs on the hepatobiliary 
disposition of bile acids can be assessed. In addition, for drugs like TGZ, where the 
metabolite (e.g. TGZ sulfate) is a more potent inhibitor of transporters compared to the 
parent,142 SCH data reflect the combined effects of both the parent and the metabolite, 
providing more physiologically-relevant information.
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Pedersen et al. compared the inhibition of TCA canalicular efflux by drugs associated with 
severe DILI and less severe/no DILI in human SCH.106 They reported that drugs associated 
with severe DILI such as cyclosporine A, ritonavir, rosiglitazone, and TGZ significantly 
reduced the canalicular efflux of TCA. On the other hand, drugs with less severe or no DILI 
(i.e., mifepristone, isradipine, budesonide, and glyburide) showed minimal effects on the 
canalicular efflux of TCA in human SCH, despite the fact that they exhibited similar potency 
towards BSEP inhibition in membrane vesicle assays. These results suggest that human SCH 
can decrease false positives that occur with membrane vesicle assays and thus, can be used 
to differentiate BSEP inhibitors associated with severe DILI from those with less DILI 
liabilities. A study by Chatterjee et al. also concluded that SCH are a useful model system to 
predict hepatotoxic potential of drugs mediated by bile acid transport inhibition.143 In their 
study, a urea assay was performed after incubation of human SCH with cholestatic and non-
cholestatic compounds to assess functional changes in hepatocytes. The drug-induced 
cholestatic index (DICI), the relative residual urea formation in SCH co-incubated with 
drugs and bile acids as compared to urea formation in SCH incubated with drugs alone, was 
calculated. Cholestatic compounds (e.g., cyclosporine A, TGZ, chlorpromazine, bosentan, 
ticlopidine, ritonavir, and midecamycin) showed DICI≤0.8, indicating that these compounds 
had enhanced toxicity (reduced urea formation) in the presence of bile acids. Conversely, 
non-cholestatic compounds (e.g., diclofenac, valproic acid, amiodarone, and acetaminophen) 
showed DICI > 0.8 because cytotoxicity of compounds remained unchanged with bile acid 
co-incubation. Overall, these studies confirm the utility of SCH for early screening of DILI 
mediated by bile acid transport inhibition.
Use of Human-Relevant Bile Acids to Characterize Drug–Bile Acid 
Interactions in SCH—TCA, which has been used widely as a model bile acid to 
investigate drug-bile acid interactions, is a predominant bile acid species in rodents, whereas 
its contribution to the human bile acid pool is minor.144 On the other hand, CDCA and its 
conjugates are prevalent primary bile acids in humans.144 TCA, a conjugated trihydroxy bile 
acid, is less hydrophobic, and thus, less toxic, compared to the dihydroxy bile acid 
CDCA.101 Interestingly, Marion et al. reported that TGZ had differential effects on 
hepatobiliary disposition of TCA and CDCA.139 TGZ decreased cellular accumulation of 
TCA in rat SCH, consistent with earlier reports as described in the “Evaluation of Drug 
Effects on Hepatobiliary Bile Acid Disposition using SCH” section, but increased CDCA 
accumulation in hepatocytes.139 Subsequent studies revealed that TGZ significantly 
inhibited TCA uptake in suspended rat hepatocytes, whereas uptake of CDCA, which was 
mediated by a nonsaturable sodium-independent mechanism, was less affected by TGZ. 
Griffin et al. also reported that while lopinavir and ritonavir significantly decreased biliary 
excretion of both TCA and CDCA, only TCA showed increased cellular accumulation; 
intracellular CDCA levels remained unchanged.136 These data suggest that drugs have 
differential effects on individual bile acids, and that altered TCA disposition may not be 
representative of the disposition of other bile acids. Therefore, use of human-relevant, more 
cytotoxic bile acids (e.g., CDCA) may provide better insights into human DILI.
Use of Fluorescent Bile Acids as Probes to Characterize Drug–Bile Acid 
Interactions in SCH—Fluorescent bile acids are another useful tool to assess drug effects 
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on hepatobiliary disposition of bile acids. One advantage of fluorescent bile acids is that 
they can be visualized by microscopic and confocal imaging, allowing non-invasive 
assessment of hepatic bile acid disposition and high-throughput screening. 
Aminofluorescein-tagged bile acids, chenodeoxycholylglycylamidofluorescein (CDCGamF) 
and cholylglycylamidofluorescein (CGamF), have been employed to assess drug effects on 
bile acid transport in transfected cells and membrane vesicle systems.145 Interestingly, 
species differences were observed in the effects of PIs on CGamF disposition in SCH; 
atazanavir, indivanir, and darunavir potently inhibited CGamF accumulation in human SCH, 
whereas inhibitory effects in rat, dog, and pig SCH were less significant.146 Cholyl-L-lysyl-
fluorescein (CLF) is another fluorescent bile acid analogue that has been used to study drug-
bile acid interactions. Barber et al. quantified inhibition of CLF disposition by twenty-nine 
drugs in rat SCH.147 They estimated IC50 values for biliary excretion of CLF, and reported 
that all of the drugs that showed plasma Cmax/IC50 ratios > 0.1 were associated with DILI in 
humans. Interestingly, for many compounds tested, IC50 values on CLF biliary excretion 
measured in rat SCH were smaller than IC50 values measured in membrane vesicle systems 
from cells expressing BSEP or MRP2, suggesting the potential contribution of metabolites 
formed in SCH. Of note, unlike endogenous bile acids, hepatic uptake of CGamF and CLF is 
mediated predominantly by OATP, and MRP2 rather than BSEP is primarily responsible for 
the biliary excretion of CLF.146,148 A recently developed fluorescent bile acid derivative, N-
(24-[7-(4-N,N-dimethylaminosulfonyl-2,1,3-benzoxadiazole)]amino-3α,7 α,12 α-
trihydroxy-27-nor-5β-cholestan-26-oyl)-2′-aminoethanesulfonate (tauro-nor-THCA-24-
DBD), was shown to be transported by NTCP and BSEP in human and rat SCH, similar to 
endogenous bile acids; this may prove to be a useful probe for drug-bile acid interaction 
studies.149 Overall, fluorescent bile acids in the SCH system are a useful tool to study drug 
and metabolite effects on bile acid disposition in a physiologically relevant system by live 
cell analysis of bile acid biliary excretion.
Integration of SCH Data into a Systems Pharmacology Model to Predict DILI
As reviewed in the previous section, SCH data provide useful insights in terms of drug-bile 
acid interactions. These in vitro data can be integrated with physiological knowledge using a 
systems pharmacology modeling approach to predict clinical hepatotoxicity. Systems 
pharmacology modeling is a useful tool to translate mechanistic data measured in vitro to in 
vivo. DILIsym® is a quantitative systems pharmacology model of DILI that includes drug 
disposition and physiological processes involved in DILI. Multiple mechanisms of DILI 
including oxidative stress, mitochondrial dysfunction, and bile acid transport inhibition are 
represented within DILIsym®, enabling prediction of DILI in humans and preclinical 
animals.150–152 To predict bile acid-mediated DILI, a bile acid homeostasis sub-model was 
constructed within DILIsym®.153 However, to construct the sub-model, the intracellular bile 
acid concentrations that led to hepatotoxicity needed to be quantified. The relative potency 
of bile acids with respect to hepatotoxicity was investigated based on medium 
concentrations or systemic exposure using in vitro and in vivo systems,154,155 but the 
relationship between hepatocellular bile acid concentrations and toxicity had not been 
determined quantitatively. In this section, a case study is presented to demonstrate how SCH 
data were used to fill this data gap, which is essential to link bile acid kinetics to toxicity in a 
bile acid transport inhibition sub-model within DILIsym®.
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Bile Acid Toxicity Studies in SCH to Establish a Quantitative Relationship 
Between Hepatocellular Bile Acids and Toxicity—The current study investigated 
cellular exposure and toxicity of LCA and CDCA in human and rat SCH. LCA and CDCA 
were chosen because they are hydrophobic and potentially toxic bile acid species; LCA is a 
secondary bile acid formed by bacterial metabolism of CDCA in the intestinal lumen.101 
Hepatic metabolic pathways and hydrophobicity of CDCA and LCA are summarized in 
Figure 3.
On day 3 (rat) or 6 (human) of culture, SCH were incubated with LCA (0.025, 0.05, 0.1, 
0.125, 0.15, and 0.2 mM), CDCA (0.05, 0.1, 0.25, 0.375, 0.5, and 1 mM for rat SCH; 0.25, 
0.375, 0.5, 0.65, 0.8, and 1 mM for human SCH), 0.1 % DMSO (vehicle control), or 2 % 
Triton-X (positive control) for 6, 12, and 24 hr. After bile acid incubation, cytotoxicity 
(cellular ATP concentrations and LDH leakage) and intracellular bile acid concentrations 
were measured. Cytotoxicity was assessed by LDH release from damaged cells using the 
LDH-Cytotoxicity Detection Kit according to the manufacturer’s protocol. Data were 
corrected for baseline levels in vehicle control (0.1% DMSO-treated SCH) and presented as 
a percentage of positive control (2% Triton X-100-treated SCH) using the following 
equation;
Eq. 
4
The values measured after complete cell lysis using 2% Triton X-100 were considered as 
maximum cell death (100% cytotoxicity). Intracellular ATP levels were measured using 
CellTiter-Glo® Luminescent Cell Viability Assay Kit according to the manufacturer’s 
protocol. Intracellular ATP concentrations were calculated by dividing ATP amount (pmol/
well) by cellular volume (1.26 μl/well),156 and values were corrected for cell viability 
obtained from the LDH assay using the following equations;
Eq. 5
Eq. 6
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For quantification of intracellular bile acids, hepatocytes were incubated with Ca2+-free 
HBSS for 5 min to open tight junctions using B-CLEAR® technology (Qualyst Transporter 
Solutions, LLC, Durham, NC). Cell lysate samples were prepared and analyzed using liquid 
chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis as 
described previously.114 Intracellular bile acid concentrations were calculated by dividing 
the amount of bile acids (pmol/well) by the cellular volume (1.26 μl/well),156 and corrected 
for cell viability obtained from the LDH assay, as described above for intracellular ATP 
calculations. The medium or total intracellular bile acid concentrations at the half-maximal 
toxicity were estimated by performing non-linear regression analysis using a four parameter 
logistic model (GraphPad Prism version 6, La Jolla, CA).
Toxicity and Intracellular Bile Acid Exposure in LCA-Treated Rat and Human 
SCH—LCA, which is formed by bacterial 7α-dehydroxylation of CDCA in the gut lumen, 
has been reported to be the most hydrophobic and toxic bile acid species. Animals 
administered LCA have been used as a model of intrahepatic cholestasis.157,158 In the 
present study, LCA showed differential toxicity in SCH from rats and humans. In rat SCH, 
treatment with 0 – 0.2 mM LCA exerted a concentration-dependent decrease in cellular ATP 
and increase in LDH leakage (Figure 4A). In human SCH, LCA caused a delayed decrease 
in cellular ATP and minimal LDH leakage was observed (Figure 4A).
To establish a quantitative relationship between LCA-induced toxicity and hepatocellular 
exposure to LCA species, cellular concentrations of LCA and LCA conjugates were 
measured in LCA-treated SCH by LC/MS/MS analysis. In rat SCH, unconjugated LCA 
accumulated extensively (in low mM ranges) and correlated with the observed toxicity 
(Figure 4B). Interestingly, TLCA and GLCA cellular concentrations were decreased at LCA 
medium concentrations greater than 0.1 mM (Figure 4B), potentially due to altered (e.g., 
saturation, depletion) glycine- or taurine-conjugation, adaptive increases in hepatic efflux of 
these conjugates, or further metabolism (e.g., sulfation). Intracellular concentrations of LCA 
and GLCA in human SCH were comparable to those in rat SCH, whereas TLCA 
concentrations in human SCH were ~100-fold lower than rat SCH (Figure 4B). Unlike rat 
SCH, intracellular TLCA and GLCA concentrations increased with increasing LCA medium 
concentrations up to 0.2 mM in human SCH (Figure 4B).
Concentrations at the half-maximal toxicity (LC50) estimated based on medium or total 
intracellular LCA concentrations after 24 h incubation are presented in Table 2. In rat and 
human SCH, LC50 values based on total intracellular LCA concentrations were ~4–5-fold 
greater compared to those based on medium LCA concentrations due to extensive hepatic 
accumulation of unconjugated LCA (Table 2). These results suggest that estimation of LCA 
potency based on medium concentrations might overestimate the actual potency of LCA at 
the site of toxicity, if total intracellular concentrations are relevant to bile acid toxicity. On 
the other hand, LC50 values based on unbound intracellular LCA concentrations may be 
lower than those based on total intracellular LCA concentrations because of binding of bile 
acids to intracellular proteins or sequestration of bile acids within intracellular organelles. 
Assessment of unbound intracellular concentrations of bile acids by cell fractionation and 
binding studies will be necessary, if unbound concentrations are relevant to hepatotoxicity. It 
is also possible that bile acid concentrations within intracellular organelles that are sensitive 
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to bile acids (e.g., mitochondria) are more relevant to bile acid-mediated toxicity. To our 
knowledge, it still remains to be investigated whether bile acid toxicity is driven by total or 
unbound intracellular bile acid concentrations, or concentrations within sub-cellular 
organelles.
Toxicity and Intracellular Bile Acid Exposure in CDCA-Treated Rat and Human 
SCH—CDCA and conjugates are dominant bile acids in humans, whereas they contribute to 
a smaller proportion of the bile acid pool in rats and mice.144,159–161 After incubation with 0 
– 1 mM CDCA, medium concentration-dependent toxicity was observed in both rat and 
human SCH (Figure 5A). Human SCH showed delayed toxicity with a higher LC50 based on 
medium CDCA concentrations, suggesting that CDCA-mediated toxicity is less potent 
compared to rat SCH (Figure 5A, Table 2).
To establish a quantitative relationship between CDCA-induced toxicity and hepatocellular 
exposure to CDCA species, cellular concentrations of CDCA and its conjugates were 
measured in CDCA-treated SCH. In rat SCH, unconjugated CDCA and TCDCA increased 
with increasing CDCA medium concentrations, consistent with the observed toxicity (Figure 
5B). Cellular TCDCA was ~100-fold lower compared to CDCA (Figure 5B); thus, it is 
plausible that unconjugated CDCA is associated with the observed toxicity in rat SCH. LC50 
values estimated based on medium or total intracellular CDCA concentrations are presented 
in Table 2. Unlike LCA, LC50 values based on total intracellular CDCA concentrations were 
lower compared to those based on medium CDCA concentrations. This led to a lower 
intracellular LC50 of CDCA compared to LCA in rat SCH, suggesting that CDCA is a more 
potent toxicant than LCA. It is possible that other CDCA conjugates (e.g., sulfate, 
glucuronide) that were not measured in the current study might have contributed to the 
observed toxicity in SCH exposed to CDCA.
In human SCH, intracellular concentrations of all the measured CDCA species decreased at 
high CDCA medium concentrations where toxicity was observed (Figure 5B), so it is not 
clear which bile acid caused toxicity in human SCH. Further investigation of other CDCA 
metabolites may provide additional insight.
Incorporation of SCH Data into a Systems Pharmacology Model—To our 
knowledge, this is the first investigation that has established quantitative relationships 
between intracellular LCA and CDCA exposure and hepatocyte toxicity in multiple species. 
Species differences in intracellular concentrations and toxic effects of LCA and CDCA after 
exposure to the same medium concentrations of these bile acids were noted in the present 
studies. Using these in vitro data, species differences in bile acid toxicity were characterized, 
and quantitative relationships between intracellular concentrations of individual bile acids 
and toxicity were established. These relationships were incorporated into DILIsym® to link 
bile acid homeostasis and ATP dynamic sub-models.162 The toxic effects of bile acids were 
linked to decreases in cellular ATP, which is an important determinant of cellular necrosis in 
DILIsym®. Subsequently, this model was successfully employed to predict clinical DILI 
mediated by drugs that interrupt bile acid transport such as TGZ and bosentan.162,163 The 
relative safety of other BSEP inhibitors, pioglitazone and telmisartan, also was accurately 
predicted.162,163 In addition, use of a species-specific bile acid homeostasis model153 and 
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bile acid toxicity data obtained in the current study recapitulated species differences in 
hepatotoxicity of TGZ and bosentan.162,163
In the current study, intracellular LC50 levels were estimated in rat and human SCH based on 
the unconjugated LCA and CDCA concentrations because intracellular unconjugated LCA 
and CDCA concentrations were correlated with observed toxicity in rat SCH. However, it is 
possible that conjugated LCA and CDCA might cause toxicity.164–169 Additional 
experiments (e.g., treatment of SCH with conjugates) would be needed to establish the 
relationship between intracellular concentrations of LCA and CDCA conjugates and 
toxicity. Also, in the present studies, in vitro toxicity was measured after short-term 
exposure to high concentrations of bile acids, assuming that toxicity was associated with 
direct effects on hepatocytes (e.g., mitochondrial proton gradient uncoupling). A different 
experimental approach would be necessary to examine the acute effects of bile acids on non-
parenchymal cells, as well as the effects of long-term exposure to low concentrations of bile 
acids on both parenchymal and non-parenchymal cells.
Due to species differences in bile acid metabolism, substrate/inhibitor specificity of bile acid 
transporters, bile acid composition, and toxic effects of bile acids reported here and 
elsewhere, preclinical species do not reliably predict bile acid-mediated DILI in 
humans.113,158,170,171 Mechanistic modeling incorporating data generated from human-
derived in vitro systems such as human SCH would be expected to provide a more accurate 
approach to predict altered hepatic bile acid disposition and subsequent DILI in humans.
CONCLUSIONS AND FUTURE DIRECTIONS
SCH are a useful tool to study hepatobiliary drug disposition and underlying mechanisms of 
DILI. Hepatic drug metabolism and transport can be characterized in SCH from humans or 
from wild-type or transgenic animals, and combined with specific inhibitors, RNAi or other 
knockdown techniques. Application of new tools [e.g., Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR)/CRISPR-associated 9 (Cas9) and targeted genome 
editing] to modulate gene expression in the SCH system may further improve 
characterization and prediction of hepatobiliary drug disposition. Kinetic parameters (e.g., 
metabolic and transporter-mediated clearances, inhibitory potency of compounds) can be 
estimated by mechanistic modeling of SCH data.172 This information can be integrated into 
PBPK or systems pharmacology models to predict drug disposition, DDIs, or potential DILI 
in humans. Studies using SCH also can provide insight regarding mechanisms underlying 
drug-induced hepatotoxicity. Often, preclinical species are not predictive of bile-acid 
mediated DILI in humans. SCH have been used widely to investigate drug and/or metabolite 
effects on hepatobiliary disposition of bile acids, as discussed in the current manuscript. In 
addition, multiple mechanisms of hepatotoxicity can be screened simultaneously in the SCH 
system, when combined with recent technologies such as high content imaging.173
Isolation procedures, cryopreservation techniques, and culture conditions can significantly 
impact hepatocyte viability and expression/function of enzymes and transporters in SCH, 
which can influence data quality and variability. Therefore, use of carefully optimized, 
standardized protocols for preparing and culturing SCH is required to ensure reliable, 
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reproducible data. Use of commercially available, transporter certified hepatocytes or B-
CLEAR® kits can minimize these issues. Appropriate quality controls (e.g., known probe 
substrates) for each experiment must be employed to ensure enzymes and/or transporters are 
functional. When isolated and cultured appropriately, variability in SCH data will reflect 
inherent variability in hepatocytes donors. Human SCH data would be expected to exhibit 
greater variability compared to SCH from preclinical species because of genetic 
polymorphisms, underlying diseases, medications, and environmental factors. Thus, 
depending on the purpose of the study, donor selection criteria need to be carefully pre-
defined to minimize confounding effects. On the other hand, SCH isolated from special 
populations can be leveraged to study altered drug disposition in these populations (e.g., 
disease states, pediatrics, or geriatrics). Alternatively, culture conditions can be modified to 
induce disease-like characteristics (e.g., phospholipidosis, type II diabetes) or mimic specific 
physiological conditions (e.g., pregnancy) in SCH for the investigation of altered 
hepatobiliary disposition of drugs.25,174,175
Hepatocytes (parenchymal cells) account for about 60% of liver mass whereas non-
parenchymal cells such as stellate cells, sinusoidal endothelial cells, and Kupffer cells 
constitute ~40% of the liver.176 Although metabolic enzymes and transporters are expressed 
predominantly in hepatocytes, non-parenchymal cells also can influence drug disposition 
indirectly by modulating the function of enzymes and transporters through heterotypic cell-
cell contacts and cytokine release. Cross-talk between hepatocytes and non-parenchymal 
cells can stimulate adaptive responses or aggravate toxic responses upon initiation of drug-
induced hepatotoxicity. Therefore, co-culture of hepatocytes and non-parenchymal cells 
might better represent liver architecture and physiology. A recent study reported that co-
culture of hepatocytes and liver sinusoidal endothelial cells in a sandwich configuration 
maintained their phenotypes and metabolic activity for up to four weeks.177 Further 
investigations are needed to establish and characterize co-culture models of hepatocytes and 
various non-parenchymal cells.
The pioneering work of Dr. Ronald T. Borchardt and colleagues in establishing cell-based 
models (e.g., Caco-2 cells) to facilitate drug discovery and development inspired 
pharmaceutical scientists to develop new approaches to investigate drug disposition in vitro. 
One such system, the SCH model, is now a well-established tool to study hepatobiliary drug 
disposition, DDIs and DILI. In addition to serving as a useful screen in drug development, 
this model has improved mechanistic understanding of hepatocyte function. Further 
development, characterization, and meaningful refinements of the SCH model will advance 
our ability to effectively use this in vitro system to predict hepatic drug and metabolite 
disposition and toxicity. Importantly, evaluation of the factors that modulate hepatocyte 
function (e.g., disease states, medications, dietary constituents, and toxins), will lead to a 
greater understanding of hepatic transporters in health and disease.
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Abbreviations used
ANIT alpha-naphthylisothiocyanate
BEI biliary excretion index
BSEP/Bsep bile salt export pump
CA cholic acid
CDCA chenodeoxycholic acid
CDCGamF chenodeoxycholylglycylamidofluorescein
CGamF cholylglycylamidofluorescein
CIL cilexetil
CLF cholyl-L- lysyl-fluorescein
CLb, app, in vitro in vitro apparent biliary clearance
CLb, int, in vitro in vitro intrinsic biliary clearance
CLint, uptake intrinsic uptake clearance
CLint, pass intrinsic passive diffusion clearance
CLint, bile intrinsic biliary clearance
CLint, met intrinsic metabolic clearance
CLint, BL intrinsic basolateral efflux clearance
CLint, uptake, parent intrinsic uptake clearance of parent
CLint, uptake, metabolite intrinsic uptake clearance of metabolite
CLint,bile, metabolite intrinsic biliary clearance of metabolite
CLint, BL, metabolite intrinsic basolateral efflux clearance of metabolite
Kflux, metabolite first-order rate constant for flux from bile networks into 
buffer of metabolite
Km Michaelis-Menten constant
CYP cytochrome P450
UGT UDP-glucuronosyltransferase
SULT sulfotransferase
DCA deoxycholic acid
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DDI drug-drug interaction
DICI drug-induced cholestatic index
DILI drug-induced liver injury
ERA endothelin receptor antagonist
HBSS Hank’s balanced salt solution
HLMs human liver microsomes
IC50 half-maximal inhibitory concentration
Kflux first-order rate constant for flux from bile networks into 
buffer
Ki inhibition constant
LC50 concentration at the half-maximal toxicity
LCA lithocholic acid
LRP-1 lipoprotein receptor-related protein-1
MDR/Mdr multidrug resistance protein
MPA mycophenolic acid
MRP/Mrp multidrug resistance-associated protein
NTCP/Ntcp sodium taurocholate co-transporting polypeptide
OATP/Oatp organic anion transporting polypeptide
OAT/Oat organic anion transporter
OCT/Oct organic cation transporter
P-gp p-glycoprotein
PI protease inhibitor
PKC protein kinase C
PMA phorbol-12-myristate-13-acetate
PBPK physiologically-based pharmacokinetic
RSV rosuvastatin
SCH sandwich-cultured hepatocytes
SF scaling factor
TCA taurocholic acid
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TGZ troglitazone
UDCA ursodeoxycholic acid
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Figure 1. Scheme illustrating the polarized expression of transporters in human sandwich-
cultured hepatocytes
Three adjacent hepatocytes with interconnecting canalicular spaces sealed by tight junctions 
are shown. Important ATP-binding cassette (ABC) transport proteins are depicted by blue 
solid arrows denoting the direction of transport. Solute carrier (SLC) transporters are 
depicted with black double arrows. Uptake transporters in the basolateral (sinusoidal) 
membrane include the sodium taurocholate co-transporting polypeptide (NTCP); organic 
anion transporter 2 (OAT2) and OAT7; organic cation transporter 1 (OCT1); and organic 
anion transporting polypeptide 1B1 (OATP1B1), OATP1B3 and OATP2B1. The heteromeric 
organic solute transporter (OSTα/β) is also depicted on the basolateral membrane. Efflux 
transporters expressed in the hepatocyte basolateral membrane include multidrug resistance-
associated protein 3 (MRP3), MRP4 and MRP6. Canalicular (apical) efflux pumps include 
MRP2; breast cancer resistance protein (BCRP); bile-salt export pump (BSEP); MDR1 P-
glycoprotein (Pgp); and multidrug and toxin extrusion protein 1 (MATE1).
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Figure 2. Schematic diagram depicting the mechanistic pharmacokinetic models (left) and 
experimental protocols (right) in SCH
(A) Model I, uptake studies were conducted in the presence of standard HBSS, Ca2+-free 
HBSS, or standard HBSS containing rifamycin SV. (B) Model II, uptake studies were 
conducted in the presence of standard HBSS or Ca2+-free HBSS. (C) Model III, uptake and 
efflux studies were conducted in the presence of standard HBSS or Ca2+-free HBSS.
In the model schemes (left), dashed boxes represent the sampling compartments. X, V, and C 
denote the mass of substrate, compartmental volume, and substrate concentration, 
respectively. Subscripts on mass, bile and concentration terms denote the corresponding 
compartment in the model scheme, superscripts represent the presence and absence of Ca2+ 
in the pre-incubation and efflux buffer. X in parenthesis represents experimental 
measurements. Output parameters include: intrinsic uptake clearance (CLint, uptake), intrinsic 
passive diffusion clearance (CLint, pass), intrinsic biliary clearance (CLint, bile), intrinsic 
metabolic clearance (CLint, met), intrinsic basolateral efflux clearance (CLint, BL), first-order 
rate constant for flux from bile networks into buffer (Kflux), intrinsic uptake clearance of 
parent (CLint, uptake, parent), intrinsic uptake clearance of metabolite (CLint, uptake, metabolite), 
intrinsic biliary clearance of metabolite (CLint, bile, metabolite), intrinsic basolateral efflux 
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clearance of metabolite (CLint, BL, metabolite), first-order rate constant for flux from bile 
networks into buffer of metabolite (Kflux, metabolite). In the experimental protocols diagram, 
the white boxes represent incubation with Ca2+-free or standard HBSS. Grey shaded boxes 
represent inclusion of the substrate in standard HBSS during the uptake phase. Black boxes 
represent a 1-min wash with Ca2+-free or standard HBSS. The sampling times and 
incubation length are shown in this diagram as an example, but need to be adjusted 
depending on the pharmacokinetic characteristics of the substrate.
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Figure 3. Hepatic metabolic pathways of lithocholic acid (LCA) and chenodeoxycholic acid 
(CDCA)
Schematic overview of previously reported metabolic pathways of LCA and CDCA in the 
liver. The hydrophobicity indices also are presented if the data were available from the 
literature. Conjugation pathways are only shown for LCA and CDCA, but other bile acids 
are also subject to glycine-, taurine-, sulfate-, or glucuronide-conjugation. (H) major 
pathway in humans; (R) major pathway in rats; 3-KCA, 3-ketocholic acid; 6-KLCA, 6-
ketolithocholic acid; BAAT, bile acid:amino acid transferase; BACS, bile acid:coA synthase; 
CA, cholic acid; CDCA, chenodeoxycholic acid; CDCA-Gluc, chenodeoxycholic acid-
glucuronide; CDCA-S, chenodeoxycholic acid-sulfate; CYP, cytochrome P450; GCDCA, 
glycochenodeoxycholic acid; GLCA, glycolithocholic acid; HCA, hyocholic acid; HDCA, 
hyodeoxycholic acid; ILCA, isolithocholic acid; LCA, lithocholic acid; LCA-Gluc, 
lithocholic acid-glucuronide; LCA-S, lithocholic acid-sulfate; αMCA, α-muricholic acid; 
βMCA, β-muricholic acid; γMCA, γ-muricholic acid; MDCA, murideoxycholic acid; SULT, 
sulfotransferase; TCDCA, taurochenodeoxycholic acid; TLCA, taurolithocholic acid; 
TLCA-S, taurolithocholic acid-sulfate; UDCA, ursodeoxycholic acid; UGT, UDP 
glucuronosyltransferase.
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Figure 4. Toxicity and intracellular bile acid concentrations in lithocholic acid (LCA)-treated rat 
and human sandwich-cultured hepatocytes (SCH)
(A) Effects of LCA exposure on intracellular ATP and lactate dehydrogenase (LDH) 
release. Day 3 rat and day 6 human SCH were incubated with LCA (0–0.2mM) for 6hr (●), 
12hr (●), and 24hr (◆). Representative data (mean±SD of triplicate determinations) from 
n=2 independent studies. (B) Intracellular concentrations of LCA and LCA metabolites, 
glycolithocholic acid (GLCA) and taurolithocholic acid (TLCA). Day 3 rat and day 6 
human SCH were incubated with LCA (0–0.2mM) for 6hr (●), 12hr (○), and 24hr (◆). 
Intracellular LCA and LCA metabolites were measured by LC-MS/MS analysis of lysate 
after hepatocytes were incubated for 5min with Ca+2-free HBSS buffer to open tight 
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junctions using B-CLEAR®.114 Representative data (mean±SD of triplicate determinations) 
from n=1 (rat) or n=2 (human) independent studies.
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Figure 5. Toxicity and intracellular bile acid concentrations in chenodeoxycholic acid (CDCA)-
treated rat and human sandwich-cultured hepatocytes (SCH)
(A) Effects of CDCA exposure on intracellular ATP and lactate dehydrogenase (LDH) 
release. Day 3 rat and day 6 human SCH were incubated with CDCA (0–1mM) for 6hr (●), 
12hr (○), and 24hr (◆). Representative data (mean±SD of triplicate determinations) from 
n=2 independent studies. (B) Intracellular concentrations of CDCA and CDCA 
metabolites, glycochenodeoxycholic acid (GCDCA) and taurochenodeoxycholic acid 
(TLCA). Day 3 rat and day 6 human SCH were incubated with CDCA (0–1mM) for 6hr 
(●), 12hr (○), and 24hr (◆). Intracellular CDCA and CDCA metabolites were measured by 
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LC-MS/MS analysis of lysate after hepatocytes were incubated for 5min with Ca+2-free 
HBSS buffer to open tight junctions using B-CLEAR®.114 Representative data (mean±SD of 
triplicate determinations) from n=1 (rat) or n=2 (human) independent studies.
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Table 1
Output parameters, assumptions, and applications of mechanistic pharmacokinetic modeling to assess 
clearance in SCH.
Type of Model Output Parameters Comments Ref.
Model I
CLint, uptake
CLint, pass
CLint, bile
Assumptions:
• no basolateral efflux
• no Kflux
• CLint, met same as estimated from HLMs
Applications:
• substrates without basolateral efflux
• CLint, met from other systems fixed in the model
60
–
62
Model II
CLint, uptake, parent
CLint, uptake, metabolite
CLint, BL, metabolite
CLint, bile, metabolite
CLint, met
Kflux, metabolite
Assumption:
• no passive diffusion
• only metabolites effluxed into bile and medium
Applications:
• simultaneous estimation of transport clearance of parent and metabolite, as 
well as metabolic clearance
66
 178 172
Model III
CLint, uptake
CLint, BL
CLint, bile
Kflux
Assumptions:
• no passive diffusion
• no metabolism
Applications:
• accurate estimation of CLint, BL and Kflux by using a novel uptake and efflux 
protocol
• useful for substrates minimally metabolized
6967
,
68
CLint, uptake, intrinsic uptake clearance; CLint, pass, intrinsic passive diffusion clearance; CLint, bile, intrinsic biliary clearance; CLint, met, 
intrinsic metabolic clearance; CLint, BL, intrinsic basolateral efflux clearance; Kflux, first-order rate constant for flux from bile networks into 
buffer; CLint, uptake, parent, intrinsic uptake clearance of parent; CLint, uptake, metabolite, intrinsic uptake clearance of metabolite; 
CLint, bile, metabolite, intrinsic biliary clearance of metabolite; CLint, BL, metabolite, intrinsic basolateral efflux clearance of metabolite; 
Kflux, metabolite, first-order rate constant for flux from bile networks into buffer of metabolite; HLMs, human liver microsomes
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Table 2
Medium and intracellular LCA or CDCA concentrations at the half-maximal toxicity 
after 24 hr incubation
Mean (95% confidence intervals) of the LCA or CDCA concentrations at the half maximal toxicity were 
estimated based on (A) medium concentrations and (B) intracellular bile acid concentrations by fitting a four 
parameter logistic model to the data obtained from in vitro rat and human sandwich-cultured hepatocytes. 
Parameters were not estimated for CDCA in human SCH because there was no direct relationship between 
intracellular CDCA and cytotoxicity.
Toxicity Measurement LCA Rat SCH LCA Human SCH CDCA Rat SCH CDCA Human SCH
(A) LC50 based on medium LCA or CDCA concentrations (mM)
ATP 0.147 (0.132 – 0.164) 0.155 (0.136 – 0.178) 0.351 (0.292 – 0.422) 0.568 (0.532 – 0.607)
LDH 0.146 (0.140 – 0.152) N.C. 0.243 (0.205 – 0.289) 0.972 (0.968 – 0.977)
(B) LC50 based on intracellular LCA or CDCA concentrations (mM)
ATP 0.782 (0.314 – 1.95) 0.776 (0.485 – 1.24) 0.148 (0.0757 – 0.290) N.C.
LDH 0.594 (0.250 – 1.41) N.C 0.0371 (0.0114 – 0.121) N.C.
N.C: not calculated.
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